Jorge Barriuso

Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawelsobczuk.bsky.social
explains more in his Opinion piece in the #ESMODailyReporter ➡️https://ow.ly/Gr0t50YtqJj

#ESMORareCancers26

Honoured for having the opportunity to present some of our work Dr Nagaraju Prof Aziz on #appendixcancer at #ESMORareCancers26
Glad to see you back Dr Strach and Prof Deraco
Thank you Drs Shiu and Wyrwicz for moderating the session!
@myesmo.bsky.social

#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced with safety and fertility considerations. Check out the #ESMODailyReporter: https://ow.ly/8jpy50YsKVz

#ESMORareCancers26: Preliminary data with the DR5 agonist, ozekibart, added to chemotherapy indicate robust activity and a manageable safety profile in relapsed/refractory #EwingSarcoma. Learn more ➡️https://ow.ly/fR7Z50Ytqq5

#ESMODailyReporter

🏆 Congratulations to the #ESMOMeritAward recipients at #ESMORareCancers26

These young researchers were recognised for the scientific merit of their abstracts.

🔗https://ow.ly/CPuX50YsfWE
#RareCancers #Oncology #Sarcoma

In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival.
#ESMORareCancers26 #ESMODailyReporter
📌 https://ow.ly/nooJ50YsIQ9

🎉 50 years. 50,000 professionals. Advancing #oncology.
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer.

#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt

'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'

Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇

#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY

#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM

#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL

The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI

#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs).
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo

📣 Registration for #ESMOTATAsia26 is open! Join global experts in #precisiononcology and discover the latest breakthroughs in cancer #drugdevelopment

🔗 https://ow.ly/oQRg50XBOZZ

⏰ Early Registration applies until 8 April 2026.

In the #ESMODailyReporter, Eileen Yi Ling Poon discusses addressing the medical and psychosocial needs of adolescents and young adults (#AYA) w/ cancer, providing individualised treatment, targeted emotional support and age-appropriate information: https://ow.ly/O94S50XCBee

#ESMOAsia25

🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings

👉 Together, we shape the future of oncology: buff.ly/qHVAi4F

#ESMOAsia25: The CLDN18.2-targeting antibody–drug conjugate (#ADC), JS107 in combination, achieved an impressive response rate in the first-line treatment of CLDN18.2-high #GastricCancer in a phase I #ClinicalTrial.
📌 Read more: https://ow.ly/MIw750XCBfZ

#ESMODailyReporter

ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25
📌 https://ow.ly/tko150XCK64

#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation.
📌Read more: https://ow.ly/htXy50XCCKL

#ESMODailyReporter

Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection.
➡️Read more: https://ow.ly/161g50XEwRu

#ESMODailyReporter

People with a history of polyps often do not get follow-up colonoscopy after a positive FIT test, early-onset cancers are rising in Corn Belt states, and more. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...

#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE

Systematic benchmarking of high-throughput subcellular spatial transcriptomics platforms across human tumors - Nature Communications This study benchmarks four cutting-edge spatial transcriptomics platforms using human tumour tissues, performs multi-metric evaluation with multi-omics references, and presents the SPATCH portal for v...

This is a really interesting piece of work if you are interested in spatial transcriptomics (ST).
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice

www.nature.com/articles/s41...

#ESMO25: Novel tissue-agnostic biomarker approaches utilising the latest technology, including cutting-edge #AI-driven #DigitalPathology, could improve #immunotherapy response through optimised patient selection.
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq

Another outstanding discussion from Dra. Elena Élez on WSI H&Es AI used to predict response on the italian ATEZOTRIBE / AVATRIC cohorts and STELLAR-303.
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social

An amazing discussion by Dr Sharlene Gill on the updates of CHECKMATE 8HW and BREAKWATER.

👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?

#ESMODailyReporter @myesmo.bsky.social

🎥 50 years of key moments.

ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25

🔗 www.youtube.com/watch?v=dJTH...

#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3

#immunotherapy

Deeply honoured for participating in #ESSO44 Gothenburg as speaker in the session Progress in Pseudomyxoma Peritonei Therapy! @essonews.bsky.social
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona